German clinical-stage biotechnology company developing non-viral CAR-T cell therapies, including in vivo CAR-T and autologous ex vivo CAR-T programs for hematological malignancies and solid tumors
German clinical-stage biotechnology company developing non-viral CAR-T cell therapies, including in vivo CAR-T and autologous ex vivo CAR-T programs for hematological malignancies and solid tumors. Its platform uses T-cell-targeted lipid nanoparticle delivery of Sleeping Beauty transposon vectors to enable stable CAR expression without viral vectors.